PBYI - Puma Biotechnology, Inc.
| Previous Close | 11.66 |
| Open | 11.59 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 900 |
| Day's Range | 11.03 - 11.81 |
| 52 Week Range | 8.45 - 49.20 |
| Volume | 985,565 |
| Avg. Volume | 1,434,240 |
| Market Cap | 435.259M |
| Beta (3Y Monthly) | 1.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.41 |
| Earnings Date | Oct 30, 2019 - Nov 4, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.63 |
- Zacks
Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Don't?
Investors need to pay close attention to Puma Biotech (PBYI) stock based on the movements in the options market lately.
- Zacks
Roche's New Perjeta Combo Meets Goal in Breast Cancer Study
Roche's (RHHBY) new fixed-dose combination of Perjeta and Herceptin meets the primary endpoint in the phase III study for treating patients with HER2-positive early breast cancer.
- Zacks
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance
The FDA accepts for review Puma Biotech's (PBYI) sNDA that seeks an approval for Nerlynx in combination with Roche's Xeloda for treating third-line breast cancer.
- Business Wire
Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that the U.S. Food and Drug Administration has accepted for review its supplemental New Drug Application for neratinib in combination with capecitabine for the treatment of patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed therapy .
- Simply Wall St.
Puma Biotechnology (NASDAQ:PBYI) Has Debt But No Earnings; Should You Worry?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
- Zacks
Why Is Puma Biotech (PBYI) Up 16.8% Since Last Earnings Report?
Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that on September 4, 2019 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 48,750 shares of Puma common stock to five new non-executive employees. The awards were granted under Puma’s 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The awards were granted as an inducement material to the new employees entering into employment with Puma, in accordance with Nasdaq Listing Rule 5635(c)(4).
- Business Wire
Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer
LOS ANGELES-- -- First regulatory approval of NERLYNX in Latin America. NERLYNX is the first approved therapy to reduce the risk of invasive disease recurrence in HER2-positive breast cancer patients following trastuzumab-based adjuvant treatment. Up to 25% of HER2-positive early stage breast cancer patients treated with a trastuzumab-based regimen experience a recurrence. Puma Biotechnology, Inc. ...
- Benzinga
Puma's Breast Cancer Drug Accorded Orphan Drug Designation For Brain Metastases
Puma Biotechnology Inc (NASDAQ: PBYI ) shares advanced in premarket trading Wednesday on the back of an announcement concerning its breast cancer drug Nerlynx before falling after the market open. What ...
- Benzinga
The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 3) Ardelyx Inc (NASDAQ: ARDX ) ( reported positive results ...
- MarketWatch
Puma Biotech stock surges on FDA cancer drug designation
Puma Biotechnology Inc. shares rallied in the extended session Tuesday after the drug developer said the Food and Drug Administration granted its cancer treatment a special designation. Puma shares rose 7.4% after hours, following a 3% decline to close the regular session at $10.43. The company said the FDA granted an "orphan drug" designation for its drug Nerlynx for the treatment of breast cancer patients with brain metastases. An orphan drug designation gives a drug maker incentives such as grant funding toward clinical trial costs and a possible seven years of market exclusivity to treat conditions that affect 200,000 people or less in the U.S.
- Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 9:35 a.m. EDT on Tuesday, September 10, at the H.C. Wainwright 21st Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City. A live webcast of the presentation will be available on the Company’s website at www.pumabiotechnology.com.
- Business Wire
FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the Treatment of Breast Cancer Patients with Brain Metastases
Puma Biotechnology, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to NERLYNX® for the treatment of breast cancer patients with brain metastases.
- Thomson Reuters StreetEvents
Edited Transcript of PBYI earnings conference call or presentation 8-Aug-19 8:30pm GMT
Q2 2019 Puma Biotechnology Inc Earnings Call
Motley FoolPuma Biotechnology Inc (PBYI) Q2 2019 Earnings Call Transcript
PBYI earnings call for the period ending June 30, 2019.
- Zacks
Puma (PBYI) Q2 Earnings Miss, Nerlynx Sales Rise, Stock Up
Puma Biotech (PBYI) incurs wider loss in Q2. Sales of Nerlynx improve from first-quarter levels. Stock rises 23%.
- Business Wire
Puma Biotechnology Reports Second Quarter 2019 Financial Results
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2019. Unless otherwise stated, all comparisons are for the second quarter 2019 compared to the second quarter of 2018.
- Simply Wall St.
Should You Be Worried About Insider Transactions At Puma Biotechnology, Inc. (NASDAQ:PBYI)?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly...
- Motley Fool
Here's Why Puma Biotechnology Fell 24.1% in July
Investors aren't very optimistic heading into the second-quarter 2019 earnings report. Can the company prove critics wrong?
- Zacks
ArQule (ARQL) to Post Q2 Earnings: What's in the Cards?
On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.
- Zacks
Puma Biotech (PBYI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Puma Biotech (PBYI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
